Informations

At the recent ASCO Annual Meeting, Professor Michiel S. van der Heijden from the Netherlands Cancer Institute (NKI) presented the latest biomarker analysis from the Phase III NIAGARA trial. The study investigated the dynamics of urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) receiving perioperative durvalumab in…

During a recent clinical oncology symposium, Professor Matthew D. Galsky from the Icahn School of Medicine at Mount Sinai presented the primary results of the Phase 3 KEYNOTE-B15 study (also known as EV-304). This trial evaluated the efficacy and safety of perioperative enfortumab vedotin (EV) in combination with pembrolizumab for patients with cisplatin-eligible muscle-invasive bladder…

At a recent major international oncology conference, Dr. Matthew D. Galsky from Mount Sinai presented updated data from a Phase 1 clinical trial (Late-Breaking Abstract, LBA639) and associated biomarker analysis of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients with advanced urothelial carcinoma (UC). The study data were simultaneously published in the…

While radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC), it is associated with significant morbidity and long-term quality-of-life impacts. For elderly patients and those ineligible for cisplatin-based chemotherapy, effective bladder-sparing strategies are urgently needed in clinical practice. At a recent major international oncology conference, Dr. Jonathan F. Anker from Mount…

At a recent academic conference, Professor Joaquim Bellmunt from the Dana-Farber Cancer Institute, Harvard Medical School, presented the latest exploratory analysis results from the IMvigor011 trial. He provided an in-depth interpretation of the prognostic and predictive value of circulating tumor DNA (ctDNA) dynamics during adjuvant atezolizumab treatment for muscle-invasive bladder cancer (MIBC) following surgery.

During a recent oncology symposium, Dr. Jennifer King from Indiana University presented the results of a Phase II clinical trial (Abstract 587) evaluating cabozantinib in patients with relapsed/refractory germ-cell tumors (R/R GCT). This study explores the efficacy and safety of a multi-target tyrosine kinase inhibitor (TKI) in a patient population that has failed multiple lines…

In a recent academic session, Professor David F. McDermott from Beth Israel Deaconess Medical Center presented the latest findings from Part 1 of the LITESPARK-024 study. This trial evaluated the safety and preliminary efficacy of the HIF-2α inhibitor belzutifan in combination with the CDK4/6 inhibitor palbociclib in patients with previously treated advanced clear cell renal…

At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.